收藏切换
A bioequivalence study of erlotinib hydrochloride tablets in healthy Chinese subjects
收藏切换
PDF
Xiu-xin ZHONG1, 2, Shao-jing LIN2, Zi-xin DU2, Xin-yi YANG2, Liu XIAO2, Xian-zhang LIU3, Ling GUAN2
Chinese Journal of Clinical Pharmacology | 2026, 42(11) : 1567 - 1572
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2026, 42(11): 1567-1572
Pharmacokinetics and Bioequivalence Study
A bioequivalence study of erlotinib hydrochloride tablets in healthy Chinese subjects
Full
Xiu-xin ZHONG1, 2, Shao-jing LIN2, Zi-xin DU2, Xin-yi YANG2, Liu XIAO2, Xian-zhang LIU3, Ling GUAN2
Affiliations
  • 1.The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China
  • 2.The Tenth Affiliated Hospital, Southern Medical University/Dongguan People’s Hospital, Dongguan 523059, Guangdong Province, China
  • 3.Guangzhou Keruite Pharmaceutical Co., Ltd., Guangzhou 510530, Guangdong Province, China
Published: 2026-06-17 doi: 10.13699/j.cnki.1001-6821.2026.11.011
Outline
收藏切换
Objective

To analyze the bioequivalence and safety of the test and reference formulations of erlotinib hydrochloride tablets in healthy Chinese subjects under fasting conditions following a single oral dose.

Methods

The study was conducted as a randomized, open-label, two-period crossover trial. A total of 60 healthy subjects were assigned to two sequences by randomization. Under fasting conditions, subjects received a single 150 mg oral dose of either the test or reference formulation, with a 12-day washout period between doses. The plasma concentrations of erlotinib were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS), and the pharmacokinetic parameters were calculated for bioequivalence evaluation using Phoenix WinNonlin software (version 8.3).

Results

After a single oral administration of the test or reference formulation under fasting conditions, the main pharmacokinetic parameters of erlotinib hydrochloride were as follows: maximum concentration (Cmax) was (1 649.48±567.44) and (1 548.15±529.59) ng·mL-1, AUC0-last were (28 830.12±11 507.57) and (29 396.47±11 121.61) h·ng·mL-1, AUC0-inf were (30 759.13±13 789.60) and (31 132.78±12 912.53) h·ng·mL-1. The 90% confidence intervals for the geometric mean ratios of Cmax, AUC0-last, and AUC0-inf for the two formulations were 92.44%-117.31%, 87.65%-103.90% and 87.66%-104.37%, respectively, all of which were within the bioequivalence acceptance range of 80.00%-125.00%. No serious adverse events, suspected unexpected serious adverse reactions, or adverse events leading to withdrawal occurred during the trial.

Conclusion

Under fasting conditions, the test erlotinib hydrochloride tablets were bioequivalent to the reference listed drug Tarceva® in healthy Chinese subjects and the safety profile was favorable.

erlotinib hydrochloride tablets  /  bioequivalence  /  pharmacokinetics  /  healthy subjects
Xiu-xin ZHONG, Shao-jing LIN, Zi-xin DU, Xin-yi YANG, Liu XIAO, Xian-zhang LIU, Ling GUAN. A bioequivalence study of erlotinib hydrochloride tablets in healthy Chinese subjects[J]. Chinese Journal of Clinical Pharmacology, 2026 , 42 (11) : 1567 -1572 . DOI: 10.13699/j.cnki.1001-6821.2026.11.011
Year 2026 volume 42 Issue 11
PDF
215
40
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2026.11.011
  • Receive Date:2026-01-27
  • Online Date:2026-08-06
  • Published:2026-06-17
Article Data
Affiliations
History
  • Received:2026-01-27
Affiliations
    1.The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China
    2.The Tenth Affiliated Hospital, Southern Medical University/Dongguan People’s Hospital, Dongguan 523059, Guangdong Province, China
    3.Guangzhou Keruite Pharmaceutical Co., Ltd., Guangzhou 510530, Guangdong Province, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2026.11.011
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT